Last reviewed · How we verify
Prevenar 13 (Single Dose)
Prevenar 13 stimulates the body's immune system to produce antibodies against Streptococcus pneumoniae.
Prevenar 13 stimulates the body's immune system to produce antibodies against Streptococcus pneumoniae. Used for Prevention of invasive disease caused by Streptococcus pneumoniae in infants and young children.
At a glance
| Generic name | Prevenar 13 (Single Dose) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the administration of a polysaccharide conjugate vaccine, which contains 13 serotypes of Streptococcus pneumoniae. The vaccine works by inducing the production of antibodies that recognize and bind to the surface antigens of the bacteria, thereby preventing infection.
Approved indications
- Prevention of invasive disease caused by Streptococcus pneumoniae in infants and young children
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
Key clinical trials
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (PHASE1)
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (PHASE1, PHASE2)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months (PHASE2)
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age (PHASE3)
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevenar 13 (Single Dose) CI brief — competitive landscape report
- Prevenar 13 (Single Dose) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI